Cannabix Technologies Appoints VP of Technology Development
February 11 2020 - 8:45AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of marijuana breathalyzer devices
for law enforcement and the workplace is pleased to report that Dr.
Moe Paknahad has joined the Company as VP of Technology
Development. Dr. Paknahad will help direct product
development of Cannabix’s THC breathalyzer devices. Dr. Paknahad is
an Electrical Engineer who has spent last 10 years on research and
development and product development in biomedical and environmental
monitoring devices with skills in prototyping, piloting and
commercialization.
Dr. Paknahad received his PhD in electrical engineering at the
University of British Columbia (UBC) and completed his
post-doctorate at the University of Toronto. He is a specialist in
the areas of microfluidics, machine olfaction, sensors,
organ-on-chip and lab-on-chip technologies. More recently he served
as a product development specialist at CellScale Biomaterials and
VitroFlo based in Ontario developing organ-on-chip in-vitro devices
for drug screening purposes. In addition, he served as a technical
lead and co-founder of early stage company developing energy
harvesting technology. Dr. Paknahad played a significant role at
UBC helping invent microfluidic gas analysis technology which is
used for different applications ranging from human breath analysis
to gas leakage detection in natural gas infrastructures.
Dr. Raj Attariwala stated, “Dr. Paknahad has deep knowledge of
sensor technologies, pilot prototype production as well as
commercialization and will be a great addition to our technical
team for both microfluidic technologies and FAIMS.”
The Company has granted 200,000 stock options exercisable at
$.80 for period of 2 years.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable tools to market to enhance detection of marijuana
impaired driving offences on roads at a time when marijuana is
becoming legal in many global jurisdictions. Cannabix is working to
develop drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in contrast to
urine testing for THC metabolite that requires an invasive
collection and reflects usage, days or even weeks earlier. The
devices will also be useful for other practical applications such
as testing employees in the workplace where impairment by THC can
be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2023 to Sep 2024